SCHEMBL484174

SCHEMBL484174

CN(C)c1ccc(-c2ccc(-c3nc4ccccc4[nH]3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.64
NPC1 O15118 9/20 0.64
RAB9A P51151 9/20 0.64
GAA P10253 1/20 0.64
KDM4E B2RXH2 8/20 0.62
MAPT P10636 2/20 0.62
GUSB P08236 1/20 0.62
TCF4 P15884 1/20 0.62
CTNNB1 P35222 1/20 0.62
SMN1; SMN2 Q16637 6/20 0.61
ALDH1A1 P00352 6/20 0.61
HPGD P15428 3/20 0.61
TP53 P04637 2/20 0.61
HSD17B10 Q99714 2/20 0.61
POLB P06746 2/20 0.61
GFER P55789 1/20 0.61
PKM P14618 4/20 0.60
HDAC6 Q9UBN7 1/20 0.60
PKN1 Q16512 1/20 0.58
PKN2 Q16513 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL60856 0.98 AURKA (0.66) AURKANPC1RAB9AGAAKDM4E
SCHEMBL484484 0.88 NPC1 (0.61) AURKANPC1RAB9AGAAKDM4E
SCHEMBL24295036 0.86 NPC1 (0.84) NPC1RAB9AGAAKDM4EMAPT
SCHEMBL13085648 0.86 NPC1 (0.67) AURKANPC1RAB9AGAAKDM4E
SCHEMBL2178266 0.84 NPC1 (0.88) NPC1RAB9AGAAKDM4EMAPT
SCHEMBL29386825 0.84 NPC1 (0.88) NPC1RAB9AGAAKDM4EMAPT
SCHEMBL19675116 0.83 RAB9A (0.58) NPC1RAB9AGAAKDM4EMAPT
SCHEMBL2252555 0.83 NPC1 (0.92) NPC1RAB9AGAAKDM4EMAPT
SCHEMBL62491 0.83 RAB9A (0.62) NPC1RAB9AGAAKDM4EMAPT
SCHEMBL13836671 0.82 TCF4 (0.64) AURKANPC1RAB9AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411057-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2020-05-06 EP disclosed
EP-2411057-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2020-05-06 EP disclosed
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders LILLY CO ELI (US) 2013-11-14 US disclosed
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders LILLY CO ELI (US) 2013-11-14 US disclosed
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders LILLY CO ELI (US) 2013-11-14 US disclosed
US-8491869-B2 Imaging agents for detecting neurological disorders ELI LILLY AND COMPANY (US) 2013-07-23 US disclosed
EP-2411057-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS Siemens Medical Solutions USA, Inc. (US) 2012-02-01 EP disclosed
WO-2011119565-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-09-29 WO disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
WO-2010111303-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-30 WO disclosed
WO-2010111303-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-30 WO disclosed
US-20100239496-A1 Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-23 US disclosed
US-20100239496-A1 Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-23 US disclosed
US-20100239496-A1 Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 AURKA 2152/4885NPC1 68/4885RAB9A 1055/4885
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 AURKA 3118/4885NPC1 143/4885RAB9A 1434/4885
US-20100239496-A1 Imaging agents for detecting neurological disorders MAPT, APP, PSEN1 AURKA 2152/4885NPC1 68/4885RAB9A 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.